About national neonatal screening programs for phenylketonuria
Abstract
The article presents current data on national programs for screening newborns for phenylketonuria in various countries. It is noted that the results of the first neonatal screening programs contributed to the introduction and expansion of new programs in the United States and Europe. The publicity of newborn screening has had a positive impact in the US, UK and Japan. The authors believe that multistage target criteria for blood phenylalanine concentrations, policies requiring newborn screening, better financial support for newborn screening, publicity for newborn screening, national guidelines on phenylketonuria may be prospects that should be further explored in Azerbaijan.
References
van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 2021; 7(1): 36. doi: 10.1038/s41572- 021-00267-0
Hillert A, Anikster Y, Belanger-Quintana A, Alhashem AM, Alodaib A, Alahaideb L, et al. The genetic landscape and epidemiology of phenylketonuria. Am J Hum Genet 2020; 107: 234- 250. doi: 10.1016/j.ajhg.2020.06.006
Mohamed S, Elsheikh W, Al-Aqeel AI, et al. Incidence of newborn screening disorders among 56632 infants in Central Saudi Arabia. A 6-year study. Saudi Med J 2020; 41: 703-708. https://doi. org/10.15537/smj.2020.7.25147
Turkish Statistical Institute (TÜİK). Data Portal for Statistics. Available at: https://data. tuik. gov.tr/
Scarpa M, Bonham JR, Dionisi-Vici C, Prevot J, Pergent M, Meyts I, et al. Newborn screening as a fully integrated system to stimulate equity in neonatal screening in Europe. Lancet Reg. Heal. Eur. 2022, 13, 100311. doi: 10.1016/j.lanepe.2022.100311
Al-Bari AA. Current Scenario and Future Direction of Newborn Screening and Management Program for Phenylketonuria in Bangladesh. J. inborn errors metab. screen. 2022;10 doi: 10.1590/ 2326 -4594-JIEMS-2021-0024
Jones SA, Cheillan D, Chakrapani A, Church HJ, Heales S, Wu THY, et al. Application of a Novel Algorithm for Expanding Newborn Screening for Inherited Metabolic Disorders across Europe. Int. J. Neonatal Screen. 2022, 8(1), 20. doi: 10.3390/ijns8010020
Мамедова Р.Ф., Бабаев М.Ш. Неонатальный скрининг наследственных заболеваний. Bakı Universitetinin Xəbərləri. 2008; №3: 36-41.
Kreile M, Lubina O, Ozola-Zalite I, Lugovska R, Pronina N, Sterna O, et al. Phenylketonuria in the Latvian population: molecular basis, phenylalanine levels, and patient compliance. Mol Genet Metab Rep. 2020;25:100671. doi: 10.1016/j.ymgmr.2020.100671
Гусейнли Я.С., Аскерова Т.А., Гасанова Ш.И. Клинические и генетические формы, диагностика и лечение фенилкетонурии. Azərbaycan Tibb jurnalı, 2012, № 2, s. 167-170.
Toktaş İ, Sarıbaş S, Canpolat S, Erdem Ö, Özbek MN. Evaluation of patients diagnosed with phenylketonuria and biotinidase deficiency by the newborn screening program: a ten-year retrospective study. The Turkish Journal of Pediatrics 2022; 64: 985-992. doi: 10.24953/ turkjped. 2022.467
Loeber JG, Platis D, Zetterström R, Almashanu S, Boemer F, Bonham J, et al. Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010. Int. J. Neonatal Screen. 2021, 7(1), 15. doi: 10.3390/ijns7010015
Guthrie R. Blood screening for phenylketonuria. JAMA. 1961;178:863. doi: 10.1001/ jama. 1961. 03040470079019
Wieser B. Public accountability of newborn screening: collective knowing and deciding. Soc Sci Med. 2010;70(6):926-33. doi: 10.1016/j.socscimed.2009.12.001
Watson MS, Lloyd-Puryear MA, Rodney Howell R. The Progress and Future of US Newborn Screening. Int. J. Neonatal Screen. 2022; 8: 41-65. doi: 10.3390/ijns8030041
Keywords
neonatal screening
national programs
phenylketonuria
phenylalanine